COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04944368

Payam Tabarsi

Not reported

2021-06-29

Completed

RCT

Randomized

Parallel

Blind label

single-center

Prevention

inclusion criteria: - male or female ≥18 years - willing and able to comply with all study requirements, including scheduled visits, interventions, and laboratory tests - healthy adults or adults in a stable medical condition, defined as not being hospitalized within 3 months prior to the screening visit - females must not be pregnant or breastfeeding

- subjects with signs of active sars-cov-2 infection at the screening visit. - subjects with body temperature of 38 degrees celsius or greater at the screening visit or within 72 hours prior to the screening visit. - subjects with a history of any progressive or severe neurological disorders, seizure, or guillain-barre syndrome. - subjects who receive immunosuppressive or cytotoxic medications. - female subjects who are pregnant or breastfeeding or have planned to become pregnant during the study period. - subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products. - subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study. - subjects who have been vaccinated with any vaccine or vaccine candidate against sars-cov-2. - subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to 14 days after the second dose of the study injection. - subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection. - subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period. - subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion. - subjects who have donated ≥450 ml of blood or blood products within 28 days prior to the screening visit.

2

Cinnagen

18

100

Iran;Islamic Republic of

Healthy volunteers

N/A

400

Change in geometric mean concentration (GMC) for S1 binding IgG antibodies from baseline to 14 days after the second injection;Change in geometric mean concentration (GMC) for S1 binding IgG antibodies from baseline to 21 days after the first injection;Incidence of solicited adverse events;Incidence of unsolicited adverse events;Percentage of participants with seroconversion for S1 binding IgG antibodies after the first injection;Percentage of participants with seroconversion for S1 binding IgG antibodies after the second injection

None

Phase 2

[{"arm_notes": "25 \u00b5g+15 mg;2;Days0-21;IM", "treatment_id": 2301, "treatment_name": "Advax-sm adjuvant+sars-cov-2 spike (s) protein subunit vaccine", "treatment_type": "Adjuvant+protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]